Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.
The objective was to evaluate expression of second mitochondria-derived activator of caspase (Smac) expression before and after treatment in patients treated with preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer and to correlate the clinicopathological characteristics and level of Smac expression with pathologic response and outcome. Expression of biomarker was evaluated by immunohistochemistry in tumor samples from 98 patients with clinical Stage II and III rectal cancer treated with preoperative pelvic radiotherapy plus concurrent chemotherapy. All patients received a standardized total mesorectal excision procedure after a long interval of 4-6 weeks. For Smac, patients with a good response to neoadjuvant CRT tended to have higher pre-therapy levels (P = 0.007). The level of Smac expression decreased after neoadjuvant therapy (P = 0.016). High expression of Smac before CRT, and high Dworak's tumor regression grade (TRG) were significantly associated with improved 5-year disease-free survival (P < 0.05). Pretreatment nodal status also was significantly associated with 5-year disease-free survival and 5-year local relapse-free survival (P < 0.05). Multivariate analysis confirmed that the pretreatment expression of Smac and Lymph nodal status were independent prognostic factors. Our study suggests that high expression of Smac before neoadjuvant CRT could predict good outcome in locally advanced rectal cancer patients.
Department of Radiation Oncology, Shandong Tumor Hospital, Jinan 250117, China.
Hongjiang
H
Yan
Jinming
J
Yu
Renben
R
Wang
Shumei
S
Jiang
Kunli
K
Zhu
Dianbin
D
Mu
Zhongfa
Z
Xu
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D051017:Apoptosis Regulatory Proteins; D014408:Biomarkers, Tumor / Q000032:analysis; D059186:Chemoradiotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D024101:Mitochondrial Proteins / Q000096:biosynthesis*; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012004:Rectal Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D051017:Apoptosis Regulatory Proteins; D014408:Biomarkers, Tumor; C412403:DIABLO protein, human; D047908:Intracellular Signaling Peptides and Proteins; D024101:Mitochondrial Proteins
N Engl J Med. 2004 Oct 21;351(17):1731-40
15496622
Cell. 2000 Jul 7;102(1):33-42
10929711
Oncol Rep. 2004 Apr;11(4):797-802
15010875
Cancer. 1992 Jun 1;69(11):2813-9
1571913
J Biol Chem. 2003 Jun 20;278(25):23130-40
12660240
Semin Oncol. 2003 Aug;30(4 Suppl 15):26-33
14523792
Chin Med J (Engl). 2005 Feb 5;118(3):226-30
15740652
J Clin Oncol. 2005 Aug 20;23(24):5620-7
16009958
N Engl J Med. 2006 Sep 14;355(11):1114-23
16971718
Oncogene. 2003 Mar 20;22(11):1589-99
12642862
J Clin Oncol. 2006 Oct 1;24(28):4620-5
17008704
Curr Oncol Rep. 2006 May;8(3):167-73
16618380
J Cell Biol. 2001 Apr 2;153(1):221-8
11285287
Int J Colorectal Dis. 1997;12(1):19-23
9112145
Clin Oncol (R Coll Radiol). 1995;7(6):349-58
8590695
Eur J Surg Oncol. 2006 Mar;32(2):162-7
16289718
Cancer. 1985 Mar 1;55(5):967-73
3967205